Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Cygenica Introduced Novel Drug Conjugate in Glioblastoma Multiforme Treatment

CyGenica has introduced novel drug conjugate for the treatment of Glioblastoma Multiforme (GBM). 

GBM is a particularly challenging form of brain cancer, and innovative approaches to its treatment are sorely needed.

GEENIE offers a promising avenue for delivering therapeutics, including nucleotide-based treatments like antisense oligonucleotides, SiRNAs, and genome editing therapeutics.

This versatile platform has the potential to not only address GBM but also various other cancers and rare diseases, which is a testament to its versatility and potential impact in the field of medicine.

The integration of GEENIE platform to the treatment of GBM represents a pivotal moment in their journey and a significant step forward in the development of innovative therapies for challenging diseases, bringing hope to patients battling cancer and rare conditions.

U.S. Food and Drug Administration has granted orphan drug designation for their revolutionary drug conjugate for the treatment of GBM.


magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024